Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KRAS Mutant Antigen (mKRAS)
- Target
- mKRAS
- Molecular classification
- Neoantigen, Peptide, GTPase
01
Overview
KRAS mutant antigens are peptide fragments derived from mutated KRAS proteins, primarily at codon 12, acting as tumor-specific neoantigens presented by HLA class I molecules. These neoantigens can be targeted by immunotherapeutic strategies such as adoptive T cell therapy and bispecific antibodies to elicit anti-tumor immune responses.
- Other names
- Mutant KRASOncogenic KRASKRAS G12DKRAS G12VKRAS G12CKRAS G12R
02
Mechanism of action
TCR-mediated T-cell activation and cytotoxicity, antibody-mediated immune cell recruitment and cytotoxicity
03
Biological functions
Antigen presentationT-cell activationImmune response
04
Disease associations
CancerPancreatic adenocarcinomaLung adenocarcinomaColorectal carcinoma
05
Safety considerations
On-target, off-tumor toxicityCytokine release syndromeImmune-related adverse eventsTumor lysis syndrome
06
Interacting drugs
Adoptive T cell therapy
2 more in the full profile.
07
Biomarkers
KRAS mutation status (G12D, G12V, G12C, G12R, etc.)HLA typeTumor mutational burdenPD-L1 expression
Beyond the preview
Go deeper on KRAS Mutant Antigen (mKRAS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS Mutant Antigen (mKRAS).